
    
      This study is designed to investigate and characterize the safety, tolerability and PK of
      AZD9833 monotherapy (Part A, Part B-cohort 1) and in combination with palbociclib (Part B
      cohort 2) or everolimus (Part B cohort 3) and to explore the preliminary anti-tumour activity
      in Chinese patients.
    
  